Feature Knight Therapeutics “to get real” as it builds its commercial operations By Len Zehr In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its... September 20, 2016